Cefoxitin: Difference between revisions
(Text replacement - "==Source==" to "==References==") |
Ostermayer (talk | contribs) No edit summary |
||
| (6 intermediate revisions by 4 users not shown) | |||
| Line 1: | Line 1: | ||
==General== | ==General== | ||
*Type: | *Type: [[Is Generation::2nd generation]] [[Is DrugClass::cephalosporin]] | ||
*Dosage Forms: | *Dosage Forms: powder for injection | ||
*Common Trade Names: | *Dosage Strengths: 1g, 2g, 10g | ||
*Route of Administration: IV | |||
*Common Trade Names: Mefoxin | |||
==Adult Dosing== | ==Adult Dosing== | ||
*1-2g IV q6-8h | |||
==Pediatric Dosing== | ==Pediatric Dosing== | ||
*<3 months old: Safety & efficacy not established | |||
*>3 months old: 80-160 mg/kg/day IV divided q4-6hr; higher dosages should be used for more severe or serious infections | |||
==Special Populations== | ==Special Populations== | ||
*Pregnancy: | *Pregnancy: Category B | ||
*Lactation: | *Lactation: Minimal excretion in breast milk, limited data on affect to infant | ||
*Renal Dosing | *Renal Dosing | ||
** | **CrCl 30-50 mL/min: 1-2 g q8-12hr | ||
** | **CrCl 10-30 mL/min: 1-2 g q12-24hr | ||
* | **CrCl 5-9 mL/min: 500 mg-1 g q24-28hr | ||
** | **CrCl <5 mL/min: 500 mg-1 g q24-48hr | ||
* | *Hepatic Dosing: not defined | ||
==Contraindications== | ==Contraindications== | ||
*Allergy to class/drug | *Allergy to class/drug | ||
*Neonates | |||
==Adverse Reactions== | ==Adverse Reactions== | ||
| Line 25: | Line 31: | ||
===Common=== | ===Common=== | ||
*Diarrhea | |||
*Anemia, thrombocytopenia, transient leukopenia | |||
*Elevated Cr/BUN | |||
*Elevated LFTs | |||
==Pharmacology== | ==Pharmacology== | ||
*Half-life: | *Half-life: 45-60 min | ||
*Metabolism: | *Metabolism: | ||
*Excretion: | *Excretion: Unchanged in urine (85%) | ||
*Mechanism of Action: | *Mechanism of Action: Inhibits bacterial cell wall synthesis | ||
==[[Antibiotic Sensitivities]]<ref>Sanford Guide to Antimicrobial Therapy 2014</ref>== | ==[[Antibiotic Sensitivities]]<ref>Sanford Guide to Antimicrobial Therapy 2014</ref>== | ||
| Line 158: | Line 168: | ||
==References== | ==References== | ||
<references/> | <references/> | ||
[[Category:Pharmacology]] | [[Category:Pharmacology]] [[Category:ID]] | ||
Latest revision as of 16:10, 18 July 2025
General
- Type: 2nd generation cephalosporin
- Dosage Forms: powder for injection
- Dosage Strengths: 1g, 2g, 10g
- Route of Administration: IV
- Common Trade Names: Mefoxin
Adult Dosing
- 1-2g IV q6-8h
Pediatric Dosing
- <3 months old: Safety & efficacy not established
- >3 months old: 80-160 mg/kg/day IV divided q4-6hr; higher dosages should be used for more severe or serious infections
Special Populations
- Pregnancy: Category B
- Lactation: Minimal excretion in breast milk, limited data on affect to infant
- Renal Dosing
- CrCl 30-50 mL/min: 1-2 g q8-12hr
- CrCl 10-30 mL/min: 1-2 g q12-24hr
- CrCl 5-9 mL/min: 500 mg-1 g q24-28hr
- CrCl <5 mL/min: 500 mg-1 g q24-48hr
- Hepatic Dosing: not defined
Contraindications
- Allergy to class/drug
- Neonates
Adverse Reactions
Serious
Common
- Diarrhea
- Anemia, thrombocytopenia, transient leukopenia
- Elevated Cr/BUN
- Elevated LFTs
Pharmacology
- Half-life: 45-60 min
- Metabolism:
- Excretion: Unchanged in urine (85%)
- Mechanism of Action: Inhibits bacterial cell wall synthesis
Antibiotic Sensitivities[1]
Key
- S susceptible/sensitive (usually)
- I intermediate (variably susceptible/resistant)
- R resistant (or not effective clinically)
- S+ synergistic with cell wall antibiotics
- U sensitive for UTI only (non systemic infection)
- X1 no data
- X2 active in vitro, but not used clinically
- X3 active in vitro, but not clinically effective for Group A strep pharyngitis or infections due to E. faecalis
- X4 active in vitro, but not clinically effective for strep pneumonia
See Also
References
- ↑ Sanford Guide to Antimicrobial Therapy 2014